Intermittent fasting (IF) has been recognized as a potential cancer therapeutic approach but its effect on tumor growth is limited. This study demonstrates that response to IF varies between glioblastoma subtypes, with IF specifically inhibiting Tp53-driven glioblastoma due to a reshaping of the gut microbiota and subsequent altered methionine metabolism suppressing TGF- β signaling.
- Yao Lin
- ShihJung Li
- Sanqi An
